Recombinant TRAIL and agonistic antibodies to death receptors (DRs) have been in clinical trial but displayed limited anti-cancer efficacy. Lack of functional DR expression in tumors is a major ...
A pilot study of safety and efficacy of pandimex with or without paclitaxel in the treatment of advanced solid tumors No significant financial relationships to disclose. This is an ASCO Meeting ...
In work that opens a new window on fighting cancer while minimizing side effects, researchers have developed the first small molecule that interacts with a cancer-cell-surface “death receptor,” an ...
Treatment for a number of cancers and other medical conditions is transplantation with bone marrow from a genetically nonidentical individual. Researchers have now identified several molecules ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results